Naples Global Advisors LLC Has $7.40 Million Holdings in Johnson & Johnson $JNJ

Naples Global Advisors LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 48,414 shares of the company’s stock after purchasing an additional 1,655 shares during the quarter. Naples Global Advisors LLC’s holdings in Johnson & Johnson were worth $7,395,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Pure Financial Advisors LLC raised its stake in Johnson & Johnson by 40.9% during the second quarter. Pure Financial Advisors LLC now owns 28,037 shares of the company’s stock worth $4,283,000 after buying an additional 8,140 shares during the last quarter. RKL Wealth Management LLC grew its holdings in Johnson & Johnson by 0.5% during the 2nd quarter. RKL Wealth Management LLC now owns 27,808 shares of the company’s stock worth $4,248,000 after acquiring an additional 128 shares during the period. Consolidated Planning Corp raised its position in shares of Johnson & Johnson by 19.7% in the 2nd quarter. Consolidated Planning Corp now owns 6,422 shares of the company’s stock worth $981,000 after acquiring an additional 1,055 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in shares of Johnson & Johnson by 1.4% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 1,805,207 shares of the company’s stock valued at $275,745,000 after purchasing an additional 25,183 shares during the period. Finally, Clarity Financial LLC boosted its position in shares of Johnson & Johnson by 4.5% during the 2nd quarter. Clarity Financial LLC now owns 2,170 shares of the company’s stock valued at $331,000 after purchasing an additional 94 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on JNJ. Royal Bank Of Canada boosted their price target on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Johnson & Johnson in a research report on Saturday, September 27th. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Barclays upped their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Finally, The Goldman Sachs Group boosted their target price on Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $187.47.

Johnson & Johnson Stock Up 1.4%

Shares of NYSE JNJ opened at $188.51 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a 50-day moving average price of $176.18 and a 200-day moving average price of $162.83. The stock has a market capitalization of $453.98 billion, a P/E ratio of 20.16, a P/E/G ratio of 2.37 and a beta of 0.40. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $189.78.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s payout ratio is presently 55.61%.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.